CY1106359T1 - Νεες μεθοδοι και συνθεσεις πepιεχουσες οπιοειδη και ανταγωνιστες αυτων - Google Patents

Νεες μεθοδοι και συνθεσεις πepιεχουσες οπιοειδη και ανταγωνιστες αυτων

Info

Publication number
CY1106359T1
CY1106359T1 CY20071100318T CY071100318T CY1106359T1 CY 1106359 T1 CY1106359 T1 CY 1106359T1 CY 20071100318 T CY20071100318 T CY 20071100318T CY 071100318 T CY071100318 T CY 071100318T CY 1106359 T1 CY1106359 T1 CY 1106359T1
Authority
CY
Cyprus
Prior art keywords
compositions
opioids
methods
antagonists
preparing
Prior art date
Application number
CY20071100318T
Other languages
Greek (el)
English (en)
Inventor
John J. Farrar
Original Assignee
Adolor Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adolor Corporation filed Critical Adolor Corporation
Publication of CY1106359T1 publication Critical patent/CY1106359T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY20071100318T 1999-11-29 2007-03-07 Νεες μεθοδοι και συνθεσεις πepιεχουσες οπιοειδη και ανταγωνιστες αυτων CY1106359T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45080699A 1999-11-29 1999-11-29
PCT/US2000/042315 WO2001037785A2 (en) 1999-11-29 2000-11-29 Novel methods and compositions involving opioids and antagonists thereof

Publications (1)

Publication Number Publication Date
CY1106359T1 true CY1106359T1 (el) 2011-10-12

Family

ID=23789563

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100318T CY1106359T1 (el) 1999-11-29 2007-03-07 Νεες μεθοδοι και συνθεσεις πepιεχουσες οπιοειδη και ανταγωνιστες αυτων

Country Status (13)

Country Link
EP (1) EP1244447B1 (enExample)
JP (1) JP2003528819A (enExample)
AU (1) AU784541B2 (enExample)
CA (1) CA2392362A1 (enExample)
CY (1) CY1106359T1 (enExample)
DE (1) DE60032940T2 (enExample)
DK (1) DK1244447T3 (enExample)
ES (1) ES2278647T3 (enExample)
IL (2) IL149600A0 (enExample)
MX (1) MXPA02005335A (enExample)
NZ (1) NZ518562A (enExample)
PT (1) PT1244447E (enExample)
WO (1) WO2001037785A2 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
AU773642C (en) 1997-12-22 2006-04-06 Mundipharma Pty Limited Opioid agonist/antagonist combinations
EA004876B1 (ru) 2000-02-08 2004-08-26 Эро-Селтик, С.А. Устойчивые к порче композиции опиоидных агонистов для перорального введения
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
EP1404323B1 (en) * 2001-06-05 2009-10-28 The University of Chicago Use of methylnaltrexone to treat immune suppression
SI1416842T1 (sl) 2001-07-18 2009-06-30 Euro Celtique Sa Farmacevtske kombinacije oksikodona in naloksona
WO2003013433A2 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Sequestered antagonist formulations
NZ530971A (en) 2001-08-06 2004-08-27 Euro Celtique S Oral dosage forms comprising an opioid agonist with releasable and sequestered opioid antagonists
EP2316428A1 (en) 2002-04-05 2011-05-04 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
AU2003270778B2 (en) 2002-09-20 2009-10-08 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
SI2368553T1 (sl) 2003-04-08 2015-05-29 Progenics Pharmaceuticals, Inc. Farmacevtske formulacije, vsebujoče metilnatrekson
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
US6992090B2 (en) * 2003-06-16 2006-01-31 Adolor Corporation Substituted piperidine compounds and methods of their use
US7700626B2 (en) * 2004-06-04 2010-04-20 Adolor Corporation Compositions containing opioid antagonists
CA2594987A1 (en) * 2004-12-14 2006-06-22 Shionogi & Co., Ltd. Therapeutic agent for constipation
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US20060211733A1 (en) * 2005-03-04 2006-09-21 Adolor Corporation Methods of preventing and treating opioid bowel dysfunction
CN101171010B (zh) 2005-03-07 2014-09-17 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
WO2006126529A1 (ja) * 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
EP1762569A1 (en) * 2005-09-12 2007-03-14 Alcasynn Pharmaceuticals Gmbh Novel 6-amino-morphinan derivatives, method of manufacturing them and their application as analgesics
CN101426481B (zh) 2006-04-21 2012-12-05 帝斯曼知识产权资产管理有限公司 阿片受体拮抗剂的用途
PT2484346T (pt) 2006-06-19 2017-04-26 Alpharma Pharmaceuticals Llc Composições farmacêuticas
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
CA2945356C (en) 2007-03-29 2021-03-23 Progenics Pharmaceuticals, Inc. (r)-n-methylnaltrexone bromide and pharmaceutical compostitions therof useful as peripheral .mu. opioid receptor antagonist
PT2565195E (pt) 2007-03-29 2015-07-28 Wyeth Llc Antagonistas e receptor opióide periférico e respectivas utilizações
PL2137191T3 (pl) 2007-03-29 2016-12-30 Antagoniści obwodowego receptora opioidowego i ich zastosowania
MX2010001371A (es) * 2007-08-09 2010-03-10 Rensselaer Polytech Inst Carboxamidas opioides cuaternarias.
WO2009045985A1 (en) * 2007-10-01 2009-04-09 The University Of Chicago Treatment of drug-induced nausea with opioid antagonists
AU2008331235C1 (en) * 2007-11-30 2013-01-17 Purdue Pharma L.P. Benzomorphan Compounds
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
CN101959892B (zh) 2008-02-06 2014-01-08 普罗热尼奇制药公司 (r),(r)-2,2’-二-甲基纳曲酮的制备和用途
AU2009225434B2 (en) 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
KR20140141727A (ko) 2009-03-10 2014-12-10 유로-셀티큐 에스.에이. 옥시코돈 및 날록손을 포함하는 즉시 방출 제약 조성물
CA2782529C (en) 2009-12-04 2015-05-26 Alkermes, Inc. Morphinan derivatives for the treatment of drug overdose
ES2582306T3 (es) 2010-03-22 2016-09-12 Rensselaer Polytechnic Institute Derivados de morfinano que contienen un grupo carboxamida como ligandos de receptores opioides
HUE041981T2 (hu) 2010-08-23 2019-06-28 Alkermes Pharma Ireland Ltd Eljárások antipszichotikum által kiváltott súlygyarapodás kezelésére
PL2725908T3 (pl) 2011-06-29 2017-10-31 Alkermes Inc Działające obwodowo związki opioidowe
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
EP2986294A4 (en) * 2013-04-17 2016-11-16 Biopharma Works PROCESS FOR PAIN TREATMENT
EP2986295A4 (en) * 2013-04-17 2016-11-09 Biopharma Works PROCESS FOR PAIN TREATMENT
WO2015011189A1 (en) 2013-07-23 2015-01-29 Euro-Celtique S.A. A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
KR102201609B1 (ko) * 2019-04-19 2021-01-12 연성정밀화학(주) 날데메딘의 제조방법
EP4243768A1 (en) 2020-11-12 2023-09-20 Alkermes Pharma Ireland Limited Immediate release multilayer tablet

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4769372A (en) * 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
PH24752A (en) * 1987-04-16 1990-10-01 Lilly Co Eli Piperidine opioid antagonists
US5250542A (en) * 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists

Also Published As

Publication number Publication date
IL149600A0 (en) 2002-11-10
EP1244447A4 (en) 2003-06-04
ES2278647T3 (es) 2007-08-16
WO2001037785A9 (en) 2002-08-29
AU3970601A (en) 2001-06-04
DE60032940T2 (de) 2007-11-08
WO2001037785A3 (en) 2002-01-10
MXPA02005335A (es) 2003-01-28
WO2001037785A2 (en) 2001-05-31
CA2392362A1 (en) 2001-05-31
EP1244447B1 (en) 2007-01-10
DE60032940D1 (de) 2007-02-22
DK1244447T3 (da) 2007-04-23
PT1244447E (pt) 2007-02-28
EP1244447A2 (en) 2002-10-02
NZ518562A (en) 2005-04-29
AU784541B2 (en) 2006-04-27
IL149600A (en) 2010-06-16
JP2003528819A (ja) 2003-09-30

Similar Documents

Publication Publication Date Title
CY1106359T1 (el) Νεες μεθοδοι και συνθεσεις πepιεχουσες οπιοειδη και ανταγωνιστες αυτων
ES2159839T3 (es) Derivados del propano, su preparacion y su uso.
CY1106600T1 (el) Ανθεκτικη, στη φθορα συνεξωθημενη μορφη δοσολογιας που περιεχει εναν ενεργο παραγοντα και εναν ανταγωνιστικο παραγοντα και διαδικασια παρασκευης αυτης
TR199801594A2 (xx) CCR-3 resept�r antagonistleri.
IL155702A0 (en) Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5-ht2 receptor
CY1108339T1 (el) Παραγωγα spiro(2h-1-benzopyran-2,4´-piperidine) ως αναστολεις της μεταφορας γλυκινης
TR199801255T2 (xx) Vitronektin resept�r antagonistleri.
ATE349440T1 (de) Als antikrebsmittel verwendbare heterocyklische derivate
CH1175401H9 (de) Piperazin Derivate verwendbar als CCR5 Antagonist en
TR199801555T2 (xx) Topoizomeraz inhibit�rleri olarak koralin analoglar�.
DE60021282D1 (de) Carbamat-derivate als muscarin-rezeptor antonisten
HUT74992A (en) Use of serotonin antagonist indol derivatives for producing pharmaceutical compositions using for treating fibromyalgia
DE60135485D1 (de) Monozyklische oder bizyklische carbozyklen und heterozyklen als hemmer von factor xa
ES2072096T3 (es) 4-fenilpiperidinas n-sustituidas antagonistas de opioides.
ATE234274T1 (de) Derivate des adamantan
NZ517758A (en) Pyrazolopyrimidines useful as therapeutic agents
BR9206237A (pt) Uso de derivados de tetrahidrocarbazole como receptores agonistas 5-HT1.
CY1108054T1 (el) Θεραπεια της δυσκινησιας μεσω ανταγωνιστων επιλεκτικων οπιουχων mu
HUP0301573A2 (hu) Szubsztituált arilpirazinok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
CY1115249T1 (el) Συνθεση εις τη φυση απαντωσων εκτεϊνασκιδινων και σχετικων ενωσεων
EA200300593A1 (ru) Соединения пиперазинилпиразинов в качестве агонистов или антагонистов серотонин 5-ht2 рецептора
TR199902848T2 (xx) Ergolin t�revleri ve bunlar�n somatostatin resept�r antagonist olarak kullan�mlar�
TR200200359T2 (tr) Cgrp Antagonist'lerinin ve cgrp-release (Gevşeme)-Engelleyici Menopoza Bağlı Deri Kızarıklıklarında Kullanılması
TR199900732T2 (xx) PDE IV inhibe eden 2-siyanoiminoimidazol t�revleri.
ES2159488B1 (es) Procedimiento para la preparacion de derivados de pirimidona con actividad antifungica.